Aurolife FDA Thursday, June 2, 2016 0.00 Neutral

FDA Approves HYDROCODONE BITARTRATE AND IBUPROFEN — Aurolife Pharma, LLC

# FDA Approves Generic Hydrocodone Bitartrate and Ibuprofen Combination Aurolife Pharma, LLC has received FDA approval for a generic version of the hydrocodone bitartrate and ibuprofen combination tablet, potentially intensifying competition in the pain management market and putting downward pressure on pricing for this widely-used opioid-NSAID combination therapy. The approval expands treatment options for patients while offering healthcare providers and payers additional cost-effective alternatives to branded formulations.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day